comparison of Memantine and Methylphenidate in the treatment of children with ADHD
Phase 3
- Conditions
- attention deficiency hyperactivity disorder.Disturbance of activity and attention
- Registration Number
- IRCT201205157462N7
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
receiving DSM-IV-TR diagnostic criteria for ADHD; the age range of 6 to 11 years old; not using any psychiatric drugs at least 2 weeks before the research.
Exclusion criteria: having mental retardation; having any psychiatric disorders except ODD; allergic history to Memantine; having serious disorder like heart disease; uncontrolled Seizure disorder; individuals with Systolic blood pressure above 125 mmHg or resting pulse under 60 or having above 115 beats per minute.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The ADHD symptoms. Timepoint: Baseline, third and sixth weeks after intervention. Method of measurement: ADHD Rating Scale, Clinical Global Impressions Severity.
- Secondary Outcome Measures
Name Time Method Side effects. Timepoint: Baseline, third and sixth weeks after intervention. Method of measurement: Side effects quesionnaire.